In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
The term neuro means nerves and blastoma is a cancer affecting immature cells in various parts of body. Neuroblastoma is a kind of cancer that prevails most often in infants and young children. Neuroblastoma starts in sympathetic nerve ganglia in the abdomen and can develop in stomach, chest, pelvis & bones. The symptoms of neuroblastoma usually depend on the part of the body affected. The symptoms of neuroblastoma in the abdomen include abdominal pain and diarrhoea or constipation. Neuroblastoma in the chest includes symptoms such as chest pain and changes in the eyes. Neuroblastoma in most of the cases disappears or sometimes leads to a tumour. The treatment of this cancer is based on number of factors such as stage of the cancer, child’s age and several other abnormalities in the genes.
The market for neuroblastoma drugs is anticipated to record a notable CAGR around 4% during the forecast period. The major key factors driving the growth of the market include rising prevalence of cancer in children along with the increase in spending on cancer treatment. Additionally, the first drug approved for the cure of neuroblastoma that is anti-GD2 is witnessing huge demand in market owing to its site-specific action and no cytotoxic effects in body. Further, the growing birth rate globally along with the development in advanced novel therapies for the treatment of neuroblastoma is fostering the market growth. Moreover, rising awareness for the diagnosis and treatment of neuroblastoma has enabled the focus on new tumour targets for the progress in cell mediated immunotherapy agents for the cancer. Hence, these factors are estimated to fuel the growth of the market over the forecast period.
Based on treatment type, the market is segmented into chemotherapy, bone marrow transplantation, retinoid therapy, immunotherapy and surgery, out of which, chemotherapy is anticipated to witness significant growth on the back of rising usage of chemotherapy drugs such as doxorubicin and carboplatin in order to destroy the cancer cells. Moreover, chemotherapy is used as a primary treatment for cancer as it helps in the shrinkage of tumour cells which makes other treatments such as surgery or radiation possible.
The outbreak of COVID-19 pandemic has increased the vulnerability of cancer patients owing to their condition. The surge in preventive measures in order to protect the children from COVID-19 is driving the demand for diagnosis and treatment of neuroblastoma. Further, most of the key players in the market have increased their production for important drugs to cure neuroblastoma and to ensure that the patients suffering from cancer do not undergo complications. Additionally, in-depth research is conducted to understand the impact of COVID-19 on patients suffering from neuroblastoma for the development of response mechanism. Hence, these factors will account for the growth of the market over the forecast period.CLICK TO DOWNLOAD SAMPLE REPORT
High cost for the treatment of neuroblastoma and unfavourable side effects of the treatment such as diarrhoea, mouth sores, bleeding and loss of appetite are expected t0 hinder the market growth during the forecast period.
The insufficiency of trained medical professionals to cure the neuroblastoma cancer is further hampering the growth of the market.
Our in-depth analysis of neuroblastoma drugs market includes the following segments:
On the basis of regional analysis, the neuroblastoma drugs market is segmented into five major region including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market for neuroblastoma drugs in North America is anticipated to dominate the region owing to the rise in technologically enhanced drugs along with the increase in incidences of neuroblastoma. Further, growing investments in healthcare sector and approval of orphan drugs for the treatment of neuroblastoma are boosting the market growth. The Asia Pacific region is anticipated to be fastest growing market on the back of presence of emerging nations leading to surge in children cancer base. The market in Europe is estimated to witness significant growth on the account of rising number of child healthcare centres for the treatment of cancer along with the increasing awareness related to good health.
The neuroblastoma drugs market is further classified on the basis of region as follows:
Submit Your Request For Proposal (RFP)
Submit RFP Buy Now Download Research Report Sample